Source: BioSpace
Area: News
According to BioSpace, the MHRA has approved Iluvien® (intravitreal insert releasing fluocinolone acetonide for up to 36 months) for the treatment of vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
This marketing authorisation follows the recently announced approval in Austria. These approvals were preceded by completion of the Decentralized Regulatory Procedure (DCP) in the EU, in which the MHRA, serving as the Reference Member State (RMS), delivered a positive outcome for Iluvien® along with six Concerned Members States, specifically Austria, France, Germany, Italy, Spain and Portugal. Additional marketing authorisations are expected in the coming months and Alimera continues to expect Iluvien® to be available in the EU by the end of 2012.
Daily Archives: 2012/05/08
CADTH systematic review on intravitreal bevacizumab for diabetic macular oedema
Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
The Canadian Agency for Drugs and Technologies in Health (CADTH) has published the results of a systematic review of randomised controlled trials (RCTs) of intravitreal bevacizumab (IVB) for the treatment of diabetic macular oedema (DMO). The purpose of the research was to determine whether IVB provides a therapeutic advantage in terms of visual acuity, morbidity, and/or mortality, in comparison with other standard therapy (intravitreal injection of triamcinolone, pegaptanib, or ranibizumab, or other drug therapies; and laser photocoagulation), sham treatment or placebo in the treatment of this condition. The authors conducted a search of the literature, using MEDLINE, Embase, and The Cochrane Library; grey literature (literature that is not published) was identified using a focused Google search. A supplemental review based on a non-systematic literature search was conducted to further identify evidence regarding the safety of IVB use in ocular conditions; ...
Area: News
The Canadian Agency for Drugs and Technologies in Health (CADTH) has published the results of a systematic review of randomised controlled trials (RCTs) of intravitreal bevacizumab (IVB) for the treatment of diabetic macular oedema (DMO). The purpose of the research was to determine whether IVB provides a therapeutic advantage in terms of visual acuity, morbidity, and/or mortality, in comparison with other standard therapy (intravitreal injection of triamcinolone, pegaptanib, or ranibizumab, or other drug therapies; and laser photocoagulation), sham treatment or placebo in the treatment of this condition. The authors conducted a search of the literature, using MEDLINE, Embase, and The Cochrane Library; grey literature (literature that is not published) was identified using a focused Google search. A supplemental review based on a non-systematic literature search was conducted to further identify evidence regarding the safety of IVB use in ocular conditions; ...
Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting
Read clinically focused news coverage of key developments from the meeting.
Medscape Ophthalmology
Medscape Ophthalmology
Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.
Brief empathy training program improves resident physicians interactions with patients
Resident physicians' participation in a brief training program designed to increase empathy with their patients produced significant improvement in how patients perceived their interactions with the residents.
Amakem presents key preclinical data on AMA0076 at ARVO meeting
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Wet Age-Related Macular Degeneration Responds Equally To Avastin And Lucentis
The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported at an international research meeting in Fort Lauderdale, Florida.* The findings will also appear online in the leading journal Ophthalmology...
Metformin blocks uveitis in laboratory rats
University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.
Repeating trinucleotide a strong predictor of Fuchs’ dystrophy
Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a strong predictor of an individual's risk of developing the eye condition Fuchs' dystrophy. The findings were being presented today at the annual conference of the Association for Research in Vision and Ophthalmology in Orlando, Fla.
Study Proposals Could Reduce Diabetic Retinopathy Screening Costs By Around 25 Percent
Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually...
Problems In Transport Of Donated Human Retina Led Researchers To Discover New Treatment Path For Eye Disease
Sloppy shipping of a donated human retina to an Indiana University researcher studying a leading cause of vision loss has inadvertently helped uncover a previously undetected mechanism causing the disease. The discovery has led researchers to urge review of how millions of dollars are spent investigating the cause of a type of age-related macular degeneration called choroidal neovascularization...
Eyewire Crowdsources Retinal Connectome Mapping
The eye has its own connectome, the neuronal network of the retina that processes the incoming signals before it sends them off to the brain. Much of its structure is yet unknown, and now researchers are looking into the powers of crowdsourcing to process the vast amounts of data they have acquired on the structure. Eyewire, developed by neuroscien (Read more...)
New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.
Subscribe
